GU Cancers 2018 | Can atezolizumab succeed where BCG fails in bladder cancer?

Peter Black

BCG immunotherapy is one of the primary treatment options for bladder cancer patients who are ineligible for cystectomy. However, some patients continue to have persistent high-grade disease long after treatment, prompting the development of new drugs such as atezolizumab. In this video, Peter Black, MD, of the University of British Colombia, Vancouver, Canada, discusses a clinical trial investigating the efficacy of atezolizumab in BCG-unresponsive bladder cancer (NCT02844816). This interview took place at the 2018 Genitourinary Cancers Symposium in San Francisco, CA.

Share this video